.jpg?format=webp&width=780)
Iron deficiency (ID) is comorbid in up to 50% of patients with heart failure (HF) and exacerbates the disease burden. Ferric carboxymaltose (FCM) reduced HF hospitalisations and improved quality of life when used to treat ID at discharge in patients hospitalised for acute HF with left‐ventricular ejection fraction of <50% in the AFFIRM‐AHF trial. This study quantified the effect of FCM on burden of disease and the wider pharmacoeconomic implications in France, Germany, Poland, Spain and Sweden. This comprehensive evaluation of FCM therapy highlights the potential benefits that could be realised through the implementation of the ESC HF guideline recommendations regarding ID treatment.
Like
Save
Share